Search results for: Market Access
Filter search results
What do Pharmaceuticals Really Cost in the Long Run?
6 October 2017
…long-run value end up entering the marketplace, market access and other policy decisions should consider the full range of long-term costs—and not just prices at a particular point in time….
OHE Authors Develop a Supply and Demand Model of Pharmaceutical Markets to Set Cost-Effectiveness Thresholds to Maximise and Distribute Social Welfare
15 June 2020
…investing in future medical innovations with the maximum possible patient access to currently available innovations. Maximising consumer (payer) surplus though, focuses only on maximising access in the present (static efficiency),…
Overview of the Economics of the Market for Medicines in the UK
29 March 2012
…His presentation covers the key issues, from drug development through health technology assessment and market access. Economics of the Market for Medicines in the UK from Office of Health Economics…
Advancing Rare Disease Care: Challenges and Key Issues
28 February 2025
…biomarkers, accelerate drug development, and provide the evidence to support the evaluation and access to the treatments of the future. Patient access to innovation Policy levers to improve incentives for…
Incentives, Competition, and Pharmaceutical Innovation in Europe: The Case of Direct Acting Antivirals for Hepatitis C
26 July 2018
…curves and market shares demonstrate that access to DAAs was sped up in this second stage for Germany, Spain, Italy and Portugal. For France, access was already high at this…
Can Transparency Lower Prices and Improve Access to Pharmaceuticals? Not So Fast…
28 March 2019
…which were not accessible to suppliers. We recommend that such databases employ strong security protocols to prevent supplier access. Since ex-factory price reductions could be entirely offset by monopolistic or…
Risk Sharing & Patient Access Schemes Workshop
10 May 2010
On 29 June, OHE will collaborate with the Pope Woodhead consultancy to present a workshop on implementing risk sharing and patient access schemes within a market access strategy. Delivered in…
GLP-1 Receptor Agonists: Shifting Obesity Management
12 May 2025
…in NICE’s “severity modifier” policy. What’s next? As the GLP-1 therapy market expands, understanding patient and societal preferences is critical for market access, pricing and HTA decisions. A rigorous evidence…
Stuart Carroll
30 August 2023
Stuart Carroll is a senior health economist and epidemiologist with over 18 years of experience, specialising in infectious diseases and vaccines, market access, health technology appraisal, public health, and public…